WO1994019005A1 - Preparation pharmaceutique ou cosmetique comportant des enzymes, son procede de fabrication et son utilisation - Google Patents

Preparation pharmaceutique ou cosmetique comportant des enzymes, son procede de fabrication et son utilisation Download PDF

Info

Publication number
WO1994019005A1
WO1994019005A1 PCT/DE1994/000208 DE9400208W WO9419005A1 WO 1994019005 A1 WO1994019005 A1 WO 1994019005A1 DE 9400208 W DE9400208 W DE 9400208W WO 9419005 A1 WO9419005 A1 WO 9419005A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation according
preparation
pharmaceutical
skin
enzyme
Prior art date
Application number
PCT/DE1994/000208
Other languages
German (de)
English (en)
Inventor
Albert Scheller
Original Assignee
Albert Scheller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6481081&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1994019005(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Albert Scheller filed Critical Albert Scheller
Priority to AU63730/94A priority Critical patent/AU6373094A/en
Publication of WO1994019005A1 publication Critical patent/WO1994019005A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22002—Papain (3.4.22.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22004—Bromelain (3.4.22.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des préparations pharmaceutiques ou cosmétiques comportant une ou plusieurs enzymes du groupe protéinases, lysozymes, élastases, alpha-lipases et alpha-amylase ainsi que, le cas échéant, des excipients et substances auxiliaires pharmaceutiquement ou cosmétiquement acceptables. L'invention concerne en outre un procédé pour la fabrication d'une telle préparation pharmaceutique ou cosmétique et son utilisation.
PCT/DE1994/000208 1993-02-23 1994-02-22 Preparation pharmaceutique ou cosmetique comportant des enzymes, son procede de fabrication et son utilisation WO1994019005A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63730/94A AU6373094A (en) 1993-02-23 1994-02-22 Enzyme-containing pharmaceutical or cosmetic composition, process for preparing the same and its use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4305460.9 1993-02-23
DE19934305460 DE4305460C2 (de) 1993-02-23 1993-02-23 Pharmazeutische oder kosmetische, Enzyme enthaltende Zubereitung, Verfahren zu deren Herstellung und deren Verwendung

Publications (1)

Publication Number Publication Date
WO1994019005A1 true WO1994019005A1 (fr) 1994-09-01

Family

ID=6481081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1994/000208 WO1994019005A1 (fr) 1993-02-23 1994-02-22 Preparation pharmaceutique ou cosmetique comportant des enzymes, son procede de fabrication et son utilisation

Country Status (3)

Country Link
AU (1) AU6373094A (fr)
DE (1) DE4305460C2 (fr)
WO (1) WO1994019005A1 (fr)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110628A (ja) * 1995-09-19 1997-04-28 L'oreal Sa 脂漏症を処理するための活性剤としてアスコルビン酸を含む化粧用および／または皮膚科学用組成物
US5945102A (en) * 1994-11-22 1999-08-31 Phairson Medical Inc. Crustacean and fish derived multifunctional enzyme
US5958406A (en) * 1994-11-22 1999-09-28 Phairson Medical Inc. Acne treatment with multifunctional enzyme
US6030612A (en) * 1994-11-22 2000-02-29 Phairson Medical Inc. Antimicrobial uses of multifunctional enzyme
US6232088B1 (en) 1995-02-08 2001-05-15 Phairson Medical, Inc. Treatment and prevention of immune rejection reactions
WO2005120555A1 (fr) * 2004-06-10 2005-12-22 Mi An Utilisation de lysozyme humain pour preparer un medicament destine au traitement de l'acne
US7947270B2 (en) 1992-05-22 2011-05-24 Arcimboldo Ab Removing dental plaque with krill enzymes
JP2012514602A (ja) * 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
JP2012514604A (ja) * 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法
US8231870B2 (en) 2007-12-03 2012-07-31 Volopharm Gmbh Pharmaceutical preparation for treating benign prostatic hyperplasia
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US8815233B2 (en) 1999-12-17 2014-08-26 Curemark Llc Method for treating pervasive development disorders
US8921054B2 (en) 2000-11-16 2014-12-30 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US9017665B2 (en) 2008-04-18 2015-04-28 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9023344B2 (en) 2008-03-13 2015-05-05 Curemark, Llc Method of treating toxemia
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US9345721B2 (en) 2005-08-30 2016-05-24 Curemark, Llc Use of lactulose in the treatment of autism
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2168870A1 (fr) * 1993-09-15 1995-03-23 Anthony Vincent Rawlings Methode et composition pour soins de la peau
US5560910A (en) * 1994-08-26 1996-10-01 Crandall; Wilson T. Topical anti-inflammatory composition and method
DE19649097A1 (de) * 1996-11-27 1998-05-28 Beiersdorf Ag Antiadhäsive Lipasen
DE19649098A1 (de) * 1996-11-27 1998-05-28 Beiersdorf Ag Antiadhäsive Proteasen
JP2002515903A (ja) * 1997-02-12 2002-05-28 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド セリンプロテアーゼと局所レチノイドの組成物
DE19829789A1 (de) * 1998-07-03 2000-01-05 Beiersdorf Ag Gegen Akne und entzündete Comedonen wirksame Zubereitungen enthaltend Serin-Proteasen und ein oder mehrere Calciumsalze
FR2778563A1 (fr) * 1998-07-06 1999-11-19 Oreal Procede d'hydratation de la peau par une lipase
WO2009142515A1 (fr) * 2008-05-19 2009-11-26 John Sylora Composition cosmetique contenant une enzyme pancreatique
DE102018205244A1 (de) * 2018-04-09 2019-10-10 Beiersdorf Ag Kosmetische Reinigungszubereitung enthaltend Amylase

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1579878A (fr) * 1967-09-13 1969-08-29
DE2126204A1 (de) * 1970-05-27 1971-12-09 Lysozyme Products, Ine , Beverly Hills, Calif (V St A) Lysozympraparate
US4355022A (en) * 1981-07-01 1982-10-19 Interon, Inc. Method of dental treatment
WO1988000043A1 (fr) * 1986-07-07 1988-01-14 Den Mat Corporation Pate dentifrice
JPH01283206A (ja) * 1988-05-09 1989-11-14 Tadao Shiraishi 塩化リゾチーム配合トイレタリー製品
JPH02188531A (ja) * 1989-01-12 1990-07-24 Reiko Kosaka 毛髪用組成物
WO1990008555A1 (fr) * 1989-01-27 1990-08-09 Immunolytics, Inc. Procede et composition de traitement de l'hypertrophie prostatique benigne
JPH04124141A (ja) * 1990-09-13 1992-04-24 Takuo Tsuji 皮膚しわ予防・治療剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860702A (en) * 1972-07-11 1975-01-14 Schuyler Dev Corp Anti-inflammatory compositions
EP0133438A1 (fr) * 1983-01-21 1985-02-27 Advanced Drug Technology Corporation Onguent enzymatique
FR2556218B1 (fr) * 1983-12-12 1986-11-14 Gerard Alain Produit pharmaceutique pour application locale constitue par l'association d'un principe actif medicamenteux-agent enzymatique

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1579878A (fr) * 1967-09-13 1969-08-29
DE2126204A1 (de) * 1970-05-27 1971-12-09 Lysozyme Products, Ine , Beverly Hills, Calif (V St A) Lysozympraparate
US4355022A (en) * 1981-07-01 1982-10-19 Interon, Inc. Method of dental treatment
WO1988000043A1 (fr) * 1986-07-07 1988-01-14 Den Mat Corporation Pate dentifrice
JPH01283206A (ja) * 1988-05-09 1989-11-14 Tadao Shiraishi 塩化リゾチーム配合トイレタリー製品
JPH02188531A (ja) * 1989-01-12 1990-07-24 Reiko Kosaka 毛髪用組成物
WO1990008555A1 (fr) * 1989-01-27 1990-08-09 Immunolytics, Inc. Procede et composition de traitement de l'hypertrophie prostatique benigne
JPH04124141A (ja) * 1990-09-13 1992-04-24 Takuo Tsuji 皮膚しわ予防・治療剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 89-375630 [51] *
DATABASE WPI Derwent World Patents Index; AN 90-266193 [35] *
DATABASE WPI Derwent World Patents Index; AN 92-189220 [23] *
ROTE LISTE. BUNDESVERBAND DER PHARMAZEUTISCHEN INDUSTRIE E.V., EDITIO CANTOR, AULENDORF, 1992. *
STN INTERNATIONAL, KARLSRUHE *

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947270B2 (en) 1992-05-22 2011-05-24 Arcimboldo Ab Removing dental plaque with krill enzymes
US5945102A (en) * 1994-11-22 1999-08-31 Phairson Medical Inc. Crustacean and fish derived multifunctional enzyme
US5958406A (en) * 1994-11-22 1999-09-28 Phairson Medical Inc. Acne treatment with multifunctional enzyme
US6030612A (en) * 1994-11-22 2000-02-29 Phairson Medical Inc. Antimicrobial uses of multifunctional enzyme
US6232088B1 (en) 1995-02-08 2001-05-15 Phairson Medical, Inc. Treatment and prevention of immune rejection reactions
JPH09110628A (ja) * 1995-09-19 1997-04-28 L'oreal Sa 脂漏症を処理するための活性剤としてアスコルビン酸を含む化粧用および／または皮膚科学用組成物
US9624526B2 (en) 1999-12-17 2017-04-18 Curemark Llc Method for treating pervasive development disorders
US8815233B2 (en) 1999-12-17 2014-08-26 Curemark Llc Method for treating pervasive development disorders
US9624525B2 (en) 1999-12-17 2017-04-18 Curemark, Llc Method for treating pervasive development disorders
US9233146B2 (en) 2000-08-14 2016-01-12 Curemark, Llc Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US10209253B2 (en) 2000-11-16 2019-02-19 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8921054B2 (en) 2000-11-16 2014-12-30 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US9377459B2 (en) 2000-11-16 2016-06-28 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
WO2005120555A1 (fr) * 2004-06-10 2005-12-22 Mi An Utilisation de lysozyme humain pour preparer un medicament destine au traitement de l'acne
US11033563B2 (en) 2005-08-30 2021-06-15 Curemark, Llc Use of lactulose in the treatment of autism
US10350229B2 (en) 2005-08-30 2019-07-16 Curemark, Llc Use of lactulose in the treatment of autism
US9345721B2 (en) 2005-08-30 2016-05-24 Curemark, Llc Use of lactulose in the treatment of autism
US8231870B2 (en) 2007-12-03 2012-07-31 Volopharm Gmbh Pharmaceutical preparation for treating benign prostatic hyperplasia
US11045527B2 (en) 2008-03-13 2021-06-29 Curemark, Llc Method of diagnosing preeclampsia or pregnancy-induced hypertension
US9408895B2 (en) 2008-03-13 2016-08-09 Curemark, Llc Method of treating pregnancy-induced hypertension
US9925250B2 (en) 2008-03-13 2018-03-27 Curemark, Llc Method of treating proteinuria in pregnancy
US9023344B2 (en) 2008-03-13 2015-05-05 Curemark, Llc Method of treating toxemia
US9017665B2 (en) 2008-04-18 2015-04-28 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US11235038B2 (en) 2008-04-18 2022-02-01 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9687534B2 (en) 2008-04-18 2017-06-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US10272141B2 (en) 2008-04-18 2019-04-30 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US10588948B2 (en) 2008-06-26 2020-03-17 Curemark, Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US10413601B2 (en) 2008-10-03 2019-09-17 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
US9687535B2 (en) 2008-10-03 2017-06-27 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
JP2019089781A (ja) * 2009-01-06 2019-06-13 ガレナゲン リミテッド ライアビリティ カンパニー 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US11357835B2 (en) 2009-01-06 2022-06-14 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
JP2012514602A (ja) * 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
JP2017122121A (ja) * 2009-01-06 2017-07-13 ガレナゲン リミテッド ライアビリティ カンパニー 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法
JP2012514604A (ja) * 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法
US9895427B2 (en) 2009-01-06 2018-02-20 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
JP2015129135A (ja) * 2009-01-06 2015-07-16 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
US10736946B2 (en) 2009-01-06 2020-08-11 Galenagen, Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US11419821B2 (en) 2009-04-13 2022-08-23 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9415014B2 (en) 2009-04-13 2016-08-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9931302B2 (en) 2009-04-13 2018-04-03 Curemark , LLC Enzyme delivery systems and methods of preparation and use
US10098844B2 (en) 2009-04-13 2018-10-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US10716835B2 (en) 2009-10-21 2020-07-21 Curemark, Llc Methods and compositions for the prevention and treatment of influenza
US9492515B2 (en) 2011-04-21 2016-11-15 Curemark, Llc Method of treatment of schizophreniform disorder
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US10279016B2 (en) 2011-04-21 2019-05-07 Curemark, Llc Method of treatment of schizophreniform disorder
US10940187B2 (en) 2011-04-21 2021-03-09 Curemark, Llc Method of treatment of schizophreniform disorder
US11364287B2 (en) 2012-05-30 2022-06-21 Curemark, Llc Methods of treating celiac disease
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Also Published As

Publication number Publication date
DE4305460C2 (de) 1997-09-04
AU6373094A (en) 1994-09-14
DE4305460A1 (de) 1994-08-25

Similar Documents

Publication Publication Date Title
DE4305460C2 (de) Pharmazeutische oder kosmetische, Enzyme enthaltende Zubereitung, Verfahren zu deren Herstellung und deren Verwendung
US6162774A (en) Skin wash composition
US7182963B2 (en) Cosmetic and dermopharmaceutical compositions for skin prone to acne
US6475536B2 (en) Pharmaceutical and cosmetic formulations with antimicrobial activity
IE940583L (en) Topical antimicrobial pharmaceutical compositions
US4508707A (en) Hair tonic composition
DE69819443T2 (de) Antimikrobielle mittel zur topische verwendung
CA2265993C (fr) Nouvelles compositions cosmetiques antimicrobiennes
EP0209724B1 (fr) Préparation effective contre l'acné ainsi que l'utilisation d'extrait actif de chiendent
WO2000038732A1 (fr) Hyaluronate lyase utilisee dans des medicaments topiques comme agent facilitant leur penetration
DE69935140T2 (de) Verwendung von anabolika, anti-katabolischen mitteln, antioxidanzien und analgetika zum schutz, zur behandlung und reparation von bindegeweben in menschen und tieren
DE69825279T2 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
WO2001058446A1 (fr) Utilisation de solutes compatibles pour proteger des biopolymeres macromoleculaires contre une decomposition par des enzymes a pouvoir degradant
KR20000049163A (ko) 식물엑기스를 함유하는 의약 내지 화장품의 여드름치료제조성물
JP2003306438A (ja) ケモカイン発現阻害剤
DE19547991A1 (de) Kosmetische und dermatologische Zubereitungen mit einem wirksamen Gehalt an Harnsäure und Uricase
EP1591125A1 (fr) Composition pharmaceutique comprenant des extraits des lichens et d'hypericum
US20030072777A1 (en) Combinatorial anti-acne compositions
KR100879094B1 (ko) 천연 정유 성분 및 그의 하이드로졸 성분을 함유하는 여드름 개선용 화장료 조성물
DE2447627B2 (de) Antimikrobielles praeparat
ATE173624T1 (de) Synergistische pharmazeutische zusammensetungen, die triamcinolonacetonid und halcinonid enthalten
DE2729010C2 (de) Arzneimittel zur Behandlung der Cellulite und des Fettübergewichtes
DE19649098A1 (de) Antiadhäsive Proteasen
US20220015992A1 (en) Topical composition using a two-part form factor
EP1338269A1 (fr) Composition pour éclaircir la peau et pour soulager les désordres de pigmentation contenant créatinine et/ou des dérivés de créatinine comme agent actif

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CZ FI HU JP KR NO NZ RU UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase